Abstract
Ovarian cancer is one of the most common gynecological malignancies with highest mortality rate among all gynecological malignant tumors. Advanced ovarian cancer patients can obtain a survival benefit from chemotherapy, including platinum drugs and paclitaxel. In more recent years, the administration of poly-ADP ribose polymerase inhibitor to patients with BRCA mutations has significantly improved the progression-free survival of ovarian cancer patients. Nevertheless, primary drug resistance or the acquisition of drug resistance eventually leads to treatment failure and poor outcomes for ovarian cancer patients. The mechanism underlying drug resistance in ovarian cancer is complex and has not been fully elucidated. Interestingly, different non-coding RNAs (ncRNAs), such as circular RNAs, long non-coding RNAs and microRNAs, play a critical role in the development of ovarian cancer. Accumulating evidence has indicated that ncRNAs have important regulatory roles in ovarian cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically highlight the emerging roles and the regulatory mechanisms by which ncRNAs affect ovarian cancer chemoresistance. Additionally, we suggest that ncRNAs can be considered as potential diagnostic and prognostic biomarkers as well as novel therapeutic targets for ovarian cancer.
Highlights
Ovarian cancer is one of the most deadly gynecologic malignancy, there are approximately 313,959 new cases and more than 207,252 deaths annually worldwide (Sung et al, 2021)
We summarized the detailed mechanisms by which miRNAs, long non-coding RNAs (lncRNAs), and circRNAs affect ovarian cancer drug resistance
Substantial progress has been made in the diagnosis and treatment of ovarian cancer, the prognosis remains unsatisfactory
Summary
Ovarian cancer is one of the most deadly gynecologic malignancy, there are approximately 313,959 new cases and more than 207,252 deaths annually worldwide (Sung et al, 2021). MiR-1301, miR-1271, miR-429, miR-363, and miR-146b can sensitize ovarian cancer cells to DDP by inhibiting the expression of multiple EMT-related genes (Zou et al, 2017; Cao et al, 2018; Yan et al, 2018; Chen Y. et al, 2019; Yu and Gao, 2020). By inhibiting the Bcl-2 signaling pathway, several tumor suppressor miRNAs, including miR-1425p, miR-335-5p, miR-146a-5p, and miR-137 have been confirmed to sensitize ovarian cancer cells to DDP (Li et al, 2017a,b; Liu R. et al, 2018; Li X. et al, 2019).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
